Ajanta Pharma has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its manufacturing facility at Paithan, Maharashtra. The inspection has been classified as Voluntary Action Indicated (VAI).
The current Good Manufacturing Practices (cGMP) inspection of the Paithan facility was conducted by the USFDA from April 13, 2026 to April 21, 2026.
Ajanta Pharma is a specialty pharmaceutical formulation company having major focus on branded generic business across India, Asia & Africa.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1905.45 |
| Dr. Reddys Labs. | 1374.05 |
| Cipla | 1458.20 |
| Zydus Lifesciences | 1139.55 |
| Lupin | 2477.85 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: